Wedbush analyst Liana Moussatos reiterated her Outperform rating and $224 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after protocol amendments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Intercept (ICPT) NASH Trial Amendment Doesn't Change Probability of Success - Cantor FitzgeraldFebruary 10, 2017 12:39 PM Intercept (ICPT) NASH Trial Updates Offers 'Positives and Negatives' - BairdFebruary 10, 2017 12:17 PM Form SC 13G/A INTERCEPT PHARMACEUTICAL Filed by: AMERIPRISE FINANCIAL INCFebruary 10, 2017 11:51 AM Intercept Pharmaceuticals (ICPT) NASH Trial Changes Increase Probability of Success and Timely Approval - BMOFebruary 10, 2017 11:40 AM Intercept (ICPT) NASH Trial Changes Lowers the Hurdle for Success - FBRFebruary 10, 2017 11:35 AM Pre-Open Movers 02/10: (SHLD) (ICPT) (IMMU) Higher; (ONVO) (RSYS) (TCON) Lower (more...)February 10, 2017 9:30 AM UPDATE: Intercept Pharma (ICPT) Changes Main Goal in Phase Three Nash Study with OCA - BloombergFebruary 10, 2017 8:37 AM Intercept Pharma (ICPT) Falls 10% Ahead of Update on Phase 3 Trial of OCA February 10, 2017 8:18 AM Intercept Pharma (ICPT) to Provide Update on Phase 3 REGENERATE Trial of OCA in NASH TodayFebruary 10, 2017 7:05 AM Intercept to Provide Update on Phase 3 REGENERATE Trial of Obeticholic Acid for the Treatment of NASH Patients with Liver FibrosisFebruary 10, 2017 7:00 AM